Ask about this productRelated genes to: Cst6 antibody
- Gene:
- CST6 NIH gene
- Name:
- cystatin E/M
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 11q13.1
- Locus Type:
- gene with protein product
- Date approved:
- 1996-12-12
- Date modifiied:
- 2016-10-05
Related products to: Cst6 antibody
Related articles to: Cst6 antibody
- Early detection of subclinical alloimmune activity in histologically normal kidney allografts is essential for improving long-term graft outcomes. Prior studies suggest that subtle molecular alterations precede functional decline; however, independent validation and systematic assessment across multiple timepoints remain limited. - Source: PubMed
Publication date: 2026/05/15
Filho Valbert Oliveira CostaCarneiro Bárbara CastroAlvarenga Eduarda SeveroNeto Carlos Alberto BarbosaLima Eduardo Araújo CostaRequião-Moura LúcioSandes-Freitas Tainá Veras deDaher Elizabeth De Francesco - Metastasis remains the primary cause of mortality in lung adenocarcinoma (LUAD), yet the microenvironmental drivers of this progression are not fully elucidated. In this study, we performed single-cell transcriptomic profiling on primary LUAD and multi-site metastatic lesions (lymph nodes, pleura, and brain), complemented by spatial transcriptomics and multiplex immunohistochemistry (mIHC) to map the tumor microenvironment (TME). Single-cell analysis identified a conserved subset of CST6 + epithelial cells and SPP1 + macrophages significantly enriched at metastatic sites. Integrated spatial analysis and mIHC verification revealed that the physical proximity of these two subsets establishes a pro-metastatic microenvironment. In vitro co-culture experiments and secretome analysis further demonstrated that the CST6-SPP1 interaction triggers the secretion of pro-metastatic factors, such as TGF-beta and MMP9, which significantly enhances tumor cell invasion and migration. Furthermore, bioinformatic analyses suggest that this coordinated infiltration is associated with the formation of an immunosuppressive microenvironment, potentially leading to reduced lymphocyte infiltration and decreased TCR richness. In conclusion, our findings provide novel mechanistic insights into how the interaction between CST6+ epithelial cells and SPP1 + macrophages drives LUAD metastasis. The integration of spatial and functional evidence highlights this cellular axis as a potential therapeutic vulnerability, suggesting that targeting these key interactions could provide significant clinical benefits for patients at high metastatic risk. - Source: PubMed
Publication date: 2026/04/17
Li ZhilongWu XianzhenDing WeiJia Haixia - The Cystatin 6 (CST6 [also known as Cystatin E/M]) is a cysteine protease inhibitor that exhibits a dual role in various types of tumors, acting as either a suppressor or promoter. In non-oncological contexts, CST6 maintains skin barrier homeostasis, mediates preeclampsia pathosis, and is associated with conditions such as pulmonary fibrosis. Diagnostic approaches involving CST6 include liquid biopsy and tissue analysis, while therapeutic strategies involve epigenetic activation and recombinant protein administration, among others. Overall, as a key variable driving multisystem pathologies through protease-substrate imbalance, CST6 represents a molecular target for precision diagnostics and therapeutics across diseases, necessitating in-depth investigation into its functions. Based on the existing research, this review summarizes the fundamental theory of CST6 in disease, considers its roles in both oncological and non-oncological conditions, and proposes future research directions. - Source: PubMed
Publication date: 2026/03/13
Li YunhuaLong XuehongChen GangwenWu YongkangWen HonghuaTang ChunrongLiu Yi - AGILE (NCT04746183) is a Phase Ib/IIa platform, evaluating candidates to treat COVID-19. Candidate Specific Trial 6 evaluated the safety and optimal dose of a novel intravenous formulation of favipiravir in a dose-escalating, open-label, randomized, controlled, Bayesian adaptive Phase Ib trial. Hospitalized adults with PCR-confirmed SARS-CoV-2 infection, within 14 days of symptomatic COVID-19 were randomized 2:1 in groups of 6 (n = 4 favipiravir, n = 2 standard of care) to ascending doses of intravenous favipiravir twice daily (b.i.d.) for 7 days or standard of care. Clinical data, safety evaluations, virology and pharmacokinetic samples were collected. The primary outcome was safety. Secondary outcomes included clinical, pharmacokinetic and virological endpoints. Twenty-four participants enrolled between September 10, 2022 and November 1, 2023 [10/24 female; median age 74 years (range 52-93)]. Favipiravir was well tolerated despite a high background rate of unrelated adverse events. No dose limiting toxicities were observed, with a model-predicted dose limiting toxicity risk of 16.8% and probability of unacceptable toxicity of 2.7% at the highest dose level. No serious adverse events were deemed related to favipiravir but an expected association with asymptomatic, transient hyperuricemia was observed. Favipiravir exposures increased disproportionally to dose with significant accumulation in plasma, but with marked variability between participants within each cohort. This novel formulation of favipiravir was safe at sustained high doses that reached pre-specified pharmacokinetic targets in a study group with frailty and complex health profiles. We consider doses up to 2,400 mg b.i.d. to be safe for further evaluation. - Source: PubMed
Publication date: 2026/03/18
Rowland TimFitzGerald RichardChallenger ElizabethDickinson LauraElse Laura JWalker LaurenHale ColinShaw VictoriaKelly CallumLyon RebeccaGibney JenniferDhamani KarimIrwin MargaretEnever YvanneTetlow MichelleWood WilliamReynolds HelenChiong JustinOsanlou OrodPertinez HenryBullock KatieGreenhalf WilliamOwen AndrewLalloo David GJacobs MichaelHiscox Julian AJaki ThomasMozgunov PavelSaunders GeoffreyGriffiths GarethKhoo Saye HFletcher Thomas E - Preeclampsia (PE) complicates 2-8% of pregnancies and involves placental hypoxia and HIF-pathway activation, especially in early-onset PE (eoPE). Chemical mimetics like cobalt (II) chloride (CoCl) and oxyquinoline derivatives model trophoblast hypoxia in vitro, yet their fidelity in recapitulating PE gene profiles remains unclear. Integrating patient tissue analyses with experimental models may reveal common markers and validate physiologically relevant paradigms. - Source: PubMed
Publication date: 2026/02/07
Knyazev EvgenyKulagin TimurAntipenko IvanTonevitsky Alexander